- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, June 8, 2018
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed included The American Journal of Managed Care® (AJMC®)'s coverage of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, held June 1-5 in Chicago, Illinois. The article, “Clinical Trials: Sharing the Road With Real-World Evidence,” covered a panel discussion on collecting and using real-world data in combination with clinical trial results to inform evidence-based care.
Thursday’s OBR Oncology daily newsfeed included ASCO coverage from AJMC®'s The Center for Biosimilars®. The article, “Researchers Report Findings on Three Biosimilar Trastuzumab Products,” covered study results that found 1-year safety and survival data of Samsung Bioepis’ SB3 support biosimilarity, central evaluations from LILAC further the clinical equivalence of Amgen’s ABP 980 and reference trastuzumab, and Biocad’s Herticad reduced the cost of trastuzumab therapy by 75%.
Decisions and Precision in Value-Based Cancer Care
January 7th 2025An Institute for Value-Based Medicine regional event in Houston, Texas, covered inconsistencies with the integration of precision medicine in oncology practices, the evolution of treatment for multiple myeloma, and more.
Read More
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
FDA Approves Tislelizumab-jsgr as First-Line Therapy for HER2– Gastric Cancers
January 2nd 2025Tislelizumab-jsgr (Tevimbra) was approved in combination with chemotherapy for the treatment of unresectable or metastatic HER2-negative (HER–) gastric or gastroesophageal junction adenocarcinoma (G/GEJ) in adults whose tumors express PD-L1.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
